Shared on 31 Oct 25
Fair value Increased 2.18%Analysts have raised their price target for TransMedics Group from $138.88 to $141.91 per share, citing expectations for stronger U.S. sales, new clinical trials, growing international momentum, and a rapidly expanding addressable market as key drivers of potential upside. Analyst Commentary Recent Street research on TransMedics Group reflects both optimism around near-term growth opportunities and a degree of caution regarding potential competitive and market challenges.
Shared on 05 Sep 25
Fair value Decreased 2.40%Analysts have trimmed their price targets for TransMedics Group to $138.88 amid growing concerns about competitive pressures and mixed surgeon feedback on the OCS platform, despite continued confidence in company growth, reflecting a modest downward revision in fair value. Analyst Commentary Bullish analysts cite TransMedics as a best-in-class growth story, raising price targets following strong results.
Shared on 30 Apr 25
Fair value Increased 4.99%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 0.28%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 22%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 24%AnalystConsensusTarget has decreased revenue growth from 24.0% to 19.5%, increased profit margin from 11.8% to 13.9% and decreased future PE multiple from 53.7x to 42.4x.